Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr:Chapter 20:20.11.1-20.11.4.
doi: 10.1002/0471142735.im2011s85.

The immune response to tumors

Michael Dougan  1 , Glenn Dranoff  1
Affiliations

The immune response to tumors

Michael Dougan et al. Curr Protoc Immunol. 2009 Apr.

Abstract

The immune response to tumors is complex. Cells of the immune system can inhibit tumor growth and progression through the recognition and rejection of malignant cells, a process referred to as immunoediting. Yet, immune responses can also promote tumor cell growth, survival, and angiogenesis through the induction of oncogenic inflammation. Immunodeficiency can predispose to the development of spontaneous and virally induced cancer, and established tumors often generate immunosuppressive microenvironments that can block productive antitumor immunity, serving as a substantial barrier to effective immune therapy. Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Literature Cited

    1. Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H., and Freeman, G.J. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111-122.
    1. Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., Cross, R., Sehy, D., Blumberg, R.S., and Vignali, D.A. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:566-569.
    1. Curiel, T.J. 2007. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117:1167-1174.
    1. Dougan, M. and Dranoff, G. 2008. Immune therapy for cancer. Annu. Rev. Immunol. 2008 Nov 13. Epub ahead of print.
    1. Dunn, G.P., Old, L.J., and Schreiber, R.D. 2004. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329-360.

LinkOut - more resources